Eric Borges

Title: Inventor Spotlight: Eric Borges from Munich

Introduction

Eric Borges is an accomplished inventor based in Munich, Germany. He holds two patents that showcase his innovative contributions to the field of biomedicine. His expertise lies in developing binding molecules that have significant applications in medical therapies.

Latest Patents

Among Eric Borges's latest inventions are patents related to binding molecules for BCMA (B-cell maturation antigen) and CD3 (a component of the T cell receptor complex). These patents describe a bispecific binding molecule that possesses two separate binding domains. The first domain is designed to bind to epitope cluster 3 of BCMA, while the second is aimed at binding the T cell CD3 receptor complex. Additionally, the patents detail a nucleic acid sequence that encodes the binding molecule, a vector encompassing this nucleic acid sequence, and a host cell that is transformed or transfected with the vector. The patents further explore the production process of the binding molecule, its medical applications, and the development of kits that contain the binding molecule.

Career Highlights

Throughout his career, Eric Borges has been affiliated with notable companies, including Amgen Inc. and Amgen Research (Munich) GmbH. His work in these organizations has contributed significantly to advancements in biotechnology and pharmacology.

Collaborations

Eric has collaborated with distinguished professionals in his field, such as Peter Kufer and Tobias Raum. These partnerships have enriched his projects and have played a critical role in the successful development of his innovative patents.

Conclusion

Eric Borges continues to be a driving force in the field of biomedical innovation. His patents on binding molecules for BCMA and CD3 not only highlight his inventive capabilities but also underline the importance of collaboration and experience in bringing groundbreaking medical solutions to fruition.